Our Team

Cytrellis’ team is comprised of seasoned leaders with deep experience developing technology and commercializing medical devices in the aesthetic industry. Our leadership team is working with some of the most well respected thought leaders in the dermatology and plastic surgery community to bring exciting new medical devices to market.

Karen Cronholm

President and CEO, Board Director

Karen has more than 25 years’ experience in the life sciences and medical device industry. She managed the body contouring franchise at Cynosure, directing marketing and product management of several aesthetic product lines for treatment of cellulite and fat reduction. She has a track record of launching exceptionally successful products and building commercial teams while spearheading operational improvements to drive productivity and increase value for the company. Previously, Karen was Head of Marketing for the Lab Solutions business at EMD Millipore. Through her 12 year tenure at EMD Millipore she successfully developed many new technologies, held various roles such as marketing manager, research and development scientist, and quality manager. She began her career in the biotech industry working with TransKaryotic Therapies. Karen has a B.S. in Microbiology from the University of New Hampshire and earned an M.B.A. with honors from Northeastern University.

Diane Marcou

Chief Financial Officer

Diane has provided financial and strategic advisory services to a number of venture-backed technology and life sciences companies, including Fractyl Laboratories Inc., T2 Biosystems, TARIS Biomedical, ByAllAccounts, Inc., Ivenix and Topera Medical. For more than 20 years working across private and public sector organizations, she has consistently built effective teams, strengthened relationships with investors, partners, customers and employees, and secured funding and negotiated critical business agreements. Previously, she was Chief Financial Officer and VP of Finance and Administration for Incentive Systems (dba Centive), a privately held venture-funded software company, and Chief Financial Officer at Workgroup Technology, a publicly traded software company with domestic and international operations. Diane earned her CPA at PricewaterhouseCoopers, formerly Coopers & Lybrand, and a BS in Business Administration from Boston College.

Patricia Krantz

VP Clinical, Regulatory and Quality

Patricia specializes in developing and executing Clinical and Regulatory strategies for companies with aesthetic dermatologic applications. Prior to Cytrellis Biosystems, Patricia worked as a Vice President of Clinical & Regulatory Affairs at Linguaflex, Inc., she also lead clinical research activities at Cynosure and Bioform Medial, securing multiple FDA clearances for various aesthetic medical devices. She has an extensive experience in startup environments and supporting strategic goals as well as overseeing Quality, Regulatory and Clinical Affairs to bring devices from concept to market. Patricia has a BS in Business from SCSU and an MBA from the University of Tampa.

Amit Munshi

Chairman of the Board

Amit Munshi has served as a member of Arena Pharmaceuticals Board of Directors, President and Chief Executive Officer since May 2016. Previously, Mr. Munshi served as Chief Executive Officer and Director of Epirus Biopharmaceuticals, Inc. from May 2012 to May 2016. Prior to Epirus, Mr. Munshi served as Chief Executive Officer of Percivia LLC, a biotechnology company (sold to Johnson & Johnson). From 2011 to 2012 Mr. Munshi was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., (sold to Allergan) from 2005 to 2010, and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. Mr. Munshi has more than 28 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management. Mr. Munshi also serves on the board of Pulmatrix Inc., (Nasdaq: PULM). Mr. Munshi is an Advisor to Associate Vice Chancellor Technology Partnerships, Research and Economic Development at the University of California Riverside and is on the Advisory Board for Peter F. Drucker and Masatoshi Ito Graduate School of Management at Claremont Graduate University. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker Graduate School of Management at Claremont Graduate University.

Keith L. Crandell

Board Director

Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed and early stage venture capital firm focused on innovations in the life and physical sciences.. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Michael Peterson

Board Director

Mike has been involved in the R&D and Product Development process for over 35 years, playing key roles in the introduction of innovative products. With Merz since 2014, he currently serves as VP, Chief Technology Officer for the Merz Device Innovation Center. He was the Vice President of R&D at Ulthera, Inc. before it was acquired by Merz in 2014. Mike has spent the last 17 years in the medical device space after leading R&D, Product Development and Project Management functions in a variety of industries including aerospace, semi-conductor and retail products. He was the VP of R&D when Select Comfort (AIRB) went public in 1998 and has been recognized as a “Distinguished Corporate Inventor” by the American Society of Patent Holders due to his product patents in multiple industries. Mike holds a Bachelor of Science in Aerospace & Mechanics from the University of Minnesota.

Frederick Beddingfield III, M.D., Ph.D.

Board Director

Frederick C. Beddingfield III, MD, PhD is Founder, President and CEO of Sienna Biopharmaceuticals. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. from March, 2013 until it was acquired by Allergan in October, 2015. Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield also served as Chief Medical Officer of Allergan Medical and led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, LATISSE®, and NATRELLE® Breast Implants. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, psoriasis, rosacea, scarring, hyperhidrosis, and hair loss.

Dr. Beddingfield earned an MD degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies, while simultaneously completing his Dermatology residency and Dermatologic Surgery fellowship at UCLA in the STAR program. He was the recipient of the Elle Genius Award in 2009. Currently, Dr. Beddingfield is a Clinical Associate Professor of Medicine/Dermatology at the UCLA School of Medicine where he has been on the faculty teaching and seeing patients since 2003. He serves on the Board of Directors of Advancing Innovation in Dermatology and is a founder of the Dermatology Summit and Dermatology Entrepreneurship Conferences.

John McDonough

Board Director

John McDonough is President and Chief Executive Officer of T2 Biosystems and has been a member of T2 Biosystem’s Board of Directors since November 2007. From 2003 to 2007, John held various positions at Cytyc Corporation, a company engaged in the design, development, manufacturing and marketing of clinical products that focus on women’s health, and ultimately served as President at Cytyc Development Corporation. John had the responsibility of designing and executing Cytyc Corporation’s growth strategy for expanding the company from a single product company with revenue of approximately $300 million to a diverse women’s health company with revenue of approximately $750 million. He led the efforts that resulted in Cytyc’s acquisition by Hologic, Inc. in October, 2007, for over $6 billion. He has served in senior executive management and CEO roles in several private and public companies. He is currently also a member of the Board of Directors at Solace Therapeutics. Mr. McDonough earned his B.S.B.A. from Stonehill College.

Rox Anderson, MD

Founder, Medical / Technology Advisor

Dr. Anderson practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT and serves on many clinical advisory boards and industry committees. He has conceived and developed many of the ground breaking laser treatments now widely used in medical care. He co-invented fractional laser treatment, and recently developed a new strategy for epidermal grafting of wounds. His research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. Dr. Anderson graduated from MIT, and then received his MD degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty where he is now Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT. Dr. Anderson has been awarded over 60 national and international patents, and has co-authored over 250 scientific books and papers.

William G. Austen, Jr. MD

Founder, Medical / Technology Advisor

Dr. Austen is the Chief of the Division of Plastic & Reconstructive Surgery and Chief of the Division of Burn Surgery at the Massachusetts General Hospital, Harvard Medical School. His laboratory focuses on translational research in the field of plastic and reconstructive surgery, with an emphasis on moving novel concepts in the field from the bench top to the bedside. Dr. Austen is a member of numerous societies including the Society of University Surgeons, the American College of Surgeons, the American Association of Plastic Surgeons, and the American Society of Plastic Surgeons. He has won numerous awards including the Best Paper of the Year in Plastics & Reconstructive Surgery 2015 and Teacher of the Year in Plastic Surgery at Harvard Medical School. Dr. Austen received his undergraduate degree at Princeton followed by his medical degree at Harvard Medical School and trained in General Surgery and Plastic Surgery at Harvard Medical School followed by a Fellowship in Craniofacial Surgery at the Royal Children’s Hospital in Melbourne, Australia.

Doug Levinson, PhD

Founder

Doug Levinson is a serial entrepreneur who has created and led numerous successful companies in the life sciences. Prior to Cytrellis, Doug was a Partner at Flagship Ventures where he co-founded and served as CEO of T2 Biosystems (TTOO) and Seventh Sense Biosystems. Doug was a member of the founding team of TransForm Pharmaceuticals and served as a member of the Management Team from the company’s initial founding through its acquisition by J&J in 2006. At TransForm, he served as Vice President of Emerging Science and Technology where he led the design, development and implementation of TransForm’s basic technology platforms and business model. Prior to TransForm, Doug was at Millennium Pharmaceuticals for 7 years, which he joined as a founding scientific team member and was responsible for establishing the company’s early scientific program in Immunology/Inflammation. Doug holds a Ph.D. in Genetics from Harvard University and a B.S. cum laude in Molecular Biology from the University of Massachusetts. He has authored numerous patents in the field of high throughput platform technologies and molecular genetics and has published extensively in scientific journals. He currently serves as the University of Virginia Biomedical Engineering Department’s Coulter Translational Partnership Oversight Committee and is a faculty member of the MIT IMPACT Program.